Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Darotropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 0.94 |
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.94 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darotropium SCHEMBL146666 | 1.00 | CHRM3 (0.94) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL3682092 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL29504618 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL16781068 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL3682091 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL524037 | 0.97 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL29355152 | 0.97 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL140648 | 0.97 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL140647 | 0.97 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4631510 | 0.92 | CHRM3 (0.90) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677795-B1 | MUSCARINIC ACETYCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2011-01-05 | — | — | EP | claimed |
| US-7576096-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-18 | — | — | US | claimed |
| US-20070244150-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-18 | — | — | US | claimed |
| US-20070105895-A1 | Muscarinic acetycholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | claimed |
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-01-17 | — | — | US | disclosed |
| US-20220324875-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-13 | — | — | US | disclosed |
| EP-3612536-B1 | OXEPINOPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3-KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-12-15 | — | — | EP | disclosed |
| EP-1962932-B1 | MEDICAMENT DISPENSER | GLAXO GROUP LTD (GB) | 2021-09-08 | — | — | EP | disclosed |
| EP-3260453-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| US-10946025-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2021-03-16 | — | — | US | disclosed |
| US-10793559-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-06 | — | — | US | disclosed |
| US-20200206237-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2020-07-02 | — | — | US | disclosed |
| US-20060019964-A1 | Antiallergens; antiinflammatory agents; rhinitis; serotonin receptor antagonist | GLAXO GROUP LIMITED (GB) | 2006-01-26 | — | — | US | disclosed |
| WO-2006003407-A2 | CHIMERIC AND HUMANISED MONOCLONAL ANTIBODIES AGAINST INTELEUKIN- 13 | GLAXO GROUP LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006000398-A1 | 2,3-BENZOXAZIN DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| WO-2006000401-A1 | SUBSTITUTED OXAZINES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005116037-A1 | PURINE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005037280-A1 | MUSCARINIC ACETYCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005005451-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005005452-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793559-B2 | Chemical compounds | PIK3CA, PIK3CD, PIK3C2B | CHRM3 3771/4885CHRM2 4440/4885CHRM1 4169/4885 |
| US-20220324875-A1 | CHEMICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | CHRM3 4065/4885CHRM2 4667/4885CHRM1 4329/4885 |
| US-10946025-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | CHRM3 4030/4885CHRM2 4500/4885CHRM1 4207/4885 |
| US-20070244150-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 19/4885 |
| US-20060019964-A1 | Antiallergens; antiinflammatory agents; rhinitis; serotonin receptor antagonist | HRH2, HRH4, HRH1 | CHRM3 734/4885CHRM2 1361/4885CHRM1 1028/4885 |
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | CDK3, CDK13, AKT3 | CHRM3 1182/4885CHRM2 1917/4885CHRM1 1223/4885 |
| US-20070105895-A1 | Muscarinic acetycholine receptor antagonists | CHRM3, CHRNA7, CHRNA2 | CHRM3 1/4885CHRM2 7/4885CHRM1 19/4885 |
| US-20200206237-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | CHRM3 4226/4885CHRM2 4504/4885CHRM1 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.